UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): October 11, 2015
CEL-SCI CORPORATION
---------------------------------
(Exact name of Registrant as specified in its charter)
Colorado 01-11889 84-0916344
----------------------- ---------------- ----------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
-----------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (703) 506-9460
N/A
------------------------------------------
(Former name or former address if changed since last report)
Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry Into a Material Definitive Agreement
On December 28, 2008, the Company issued a promissory note to Maximilian de
Clara, the Company's President and a director. In August 2014, the Note was
transferred to the de Clara Trust. The maturity date on the note was July 6,
2017.
On October 11, 2015 the parties agreed to extend the maturity date of the
Note for one year to July 6, 2018. The extension was made at the request of Lake
Whillans Vehicle I, LLC, which, as disclosed in the Company's October 14, 2015
press release, agreed to provide the Company with up to $5,000,000 in funding
for litigation expenses to support the Company's $50,000,000 arbitration claims
against the Company's former clinical research organization.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: October 15, 2015 CEL-SCI CORPORATION
By: /s/ Patricia B. Prichep
--------------------------
Patricia B. Prichep
Senior Vice President of
Operations